

Kanthou, C., Dachs, G. U., Lefley, D. V., Reyes-Aldasoro, C. C. & English, W. R. (2013). Endogenous VEGF isoform expression regulates tumour cell motility. Poster presented at the 2013 NCRI Cancer Conference, 03-11-2013 - 06-11-2013, Liverpool, UK.



**CITY UNIVERSITY
LONDON**

[City Research Online](http://www.city.ac.uk/research)

Original citation: Kanthou, C., Dachs, G. U., Lefley, D. V., Reyes-Aldasoro, C. C. & English, W. R. (2013). Endogenous VEGF isoform expression regulates tumour cell motility. Poster presented at the 2013 NCRI Cancer Conference, 03-11-2013 - 06-11-2013, Liverpool, UK.

Permanent City Research Online URL: <http://openaccess.city.ac.uk/8373/>

Copyright & reuse

City University London has developed City Research Online so that its users may access the research outputs of City University London's staff. Copyright © and Moral Rights for this paper are retained by the individual author(s) and/ or other copyright holders. All material in City Research Online is checked for eligibility for copyright before being made available in the live archive. URLs from City Research Online may be freely distributed and linked to from other web pages.

Versions of research

The version in City Research Online may differ from the final published version. Users are advised to check the Permanent City Research Online URL above for the status of the paper.

Enquiries

If you have any enquiries about any aspect of City Research Online, or if you wish to make contact with the author(s) of this paper, please email the team at publications@city.ac.uk.

Endogenous VEGF isoform expression regulates tumour cell motility

Chryso Kanthou¹, Gabriele Dachs², Diane Lefley¹, Constantino Carlos Reyes-Aldasoro³, William English¹, Gillian Tozer¹

¹Tumour Microcirculation Group, Department of Oncology, School of Medicine, University of Sheffield, Sheffield, UK, ²Mackenzie Cancer Research Group, Department of Pathology, University of Otago, Christchurch, New Zealand, ³School of Engineering and Design, Biomedical Engineering Research Group, University of Sussex, Brighton, UK

Background

Vascular endothelial growth factor-A (VEGF) is produced by most cancer cells as multiple alternatively spliced isoforms, which display distinct receptor and matrix binding characteristics. In addition to being a major inducer of tumour angiogenesis, VEGF also has complex functions in angiogenesis-independent aspects of tumour growth, but the role of individual VEGF isoforms remains poorly understood. Here we investigated the effects of endogenous VEGF isoform expression on tumour cell migration and invasion.

Method

We used a panel of mouse fibrosarcoma cells we developed (fs^{188} , fs^{164} and fs^{120}) that express single VEGF isoforms (188, 164 or 120 respectively), under endogenous promoter control. We investigated adhesion to different matrices, 2D migration and invasion through 3D collagen.

Results

Fs^{188} cells, are typically mesenchymal, form ruffles, display strong integrin-dependent adhesion and express high levels of pERK1/2 and pAKT. In contrast, fs^{164} and fs^{120} cells are not typically mesenchymal in morphology; they display weak binding to collagen, lack ruffles and align longitudinally forming long multicellular chains and abundant cell-cell contacts. On 3D collagen, fs^{188} cells remain mesenchymal while fs^{164} and fs^{120} cells adopt a rounded/amoeboid and a mix of rounded/mesenchymal morphologies respectively. Cell morphology and migration are dependent on the cytoskeleton and actinomyosin contractility, to provide traction force in mesenchymal movement, and cortical contraction for rounded amoeboid motility. Consistent with their mesenchymal characteristics, fs^{188} cells migrated faster in 2D and invaded 3D collagen more efficiently than fs^{164} or fs^{120} cells. Contractility inhibitors caused fs^{164}/fs^{120} cells to switch to a mesenchymal morphology and accelerated their migration but not that of fs^{188} cells.

Conclusion

VEGF isoforms are emerging as potential biomarkers for anti-VEGF therapies. Our results suggest that individual VEGF isoforms influence the migration and invasion strategies of tumour cells thus adding to the complexity of VEGF signaling within the tumor microenvironment.

Acknowledgements

This work was funded by Cancer Research UK.

References:

- [1] G. M. Tozer, S. Akerman, N. A. Cross, P. R. Barber, M. A. Björndahl, O. Greco, S. Harris, S. A. Hill, D. J. Honess, C. R. Ireson, K. L. Pettyjohn, V. E. Prise, C. C. Reyes-Aldasoro, C. Ruhrberg, D. T. Shima, and C. Kanthou, 'Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors', *Cancer Res.*, vol. 68, no. 7, pp. 2301–2311, Apr. 2008.
- [2] S. J. Lunt, S. Akerman, S. A. Hill, M. Fisher, V. J. Wright, C. C. Reyes-Aldasoro, G. M. Tozer, and C. Kanthou, 'Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate', *Int. J. Cancer J. Int. Cancer*, vol. 129, no. 8, pp. 1979–1989, Oct. 2011.